IMNM financials
Immunome (IMNM) financials: revenue, profit and margins by year and quarter, the balance sheet and cash flow.
IMNM income statement, yearly
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | $6.94M | $3.99M | -$214.11M | -$212.39M | -2.43 |
| 2024 | $9.04M | $9.04M | -$305.80M | -$292.96M | -5.00 |
| 2023 | $14.02M | $14.02M | -$109.53M | -$106.81M | -5.38 |
| 2022 | $0.00 | $0.00 | -$36.90M | -$36.90M | -3.09 |
| 2021 | $0.00 | $0.00 | -$25.20M | -$24.71M | -2.14 |
| 2020 | $0.00 | -$755.00K | -$12.26M | -$17.84M | -1.69 |
- IMNM revenue was $6.94M in fiscal 2025, net income -$212.39M.
Updated 2026-11-07 11:56 UTC